Editorials
Editorials
The Viet Nam Resistance Project Tackles Looming Antibiotic Crisis
Researchers are collaborating with 16 hospitals in Vietnam to strengthen national evidence-based control of antibiotic use in the country.
Cell Therapies Are Gaining Momentum In Asia, Says Lonza’s Kim Raineri
There is a healthy pipeline of cell therapies coming from Asia, says Mr. Kim Raineri, Business Director at Lonza Bioscience Singapore.
Why Do Indian Students Take Up Engineering Degrees?
Dr. Pushkar, a faculty member at BITS Pilani-Goa, discusses the reasons that motivate students to take up engineering degrees in India.
Is The Asian Space Science Drive Harming Development?
Are the large sums of money invested into building prestigious space programs diverting funding from key areas such as health and education?
SE Asia’s Start-Up Scene Is Promising: Edgar Hardless, Singtel Innov8 CEO
“I believe that these are exciting times for entrepreneurs, investors and Southeast Asia,” says Mr. Edgar Hardless, CEO of Singtel Innov8, at the recent InnovFest2013.
Family Planning Spurs Development In Asia
Family planning is central to national economic development in Asia, writes Amy Tsui, Director of the Bill and Melinda Gates Institute of Population and Reproductive Health.
Science’s Lone Voice In The Philippine Congress
In the upcoming elections, a political party representing science aims to retain its seat and continue to influence policy, reports Crispin Maslog.
The Nonsense Of Biofuels: Thoughts From A Nobel Prize Winner
Prof. Hartmut Michel calls for resources used in biofuel production to be used instead to harvest solar energy with photovoltaic cells.
The Asian Scientist Spotlight: 2012 Nobel Laureate Dr. Shinya Yamanaka
During a recent visit to Singapore, Dr. Shinya Yamanaka candidly discussed his early career, what inspires him, and the challenges he faced leading up to the 2012 Nobel Prize.
5 Take-Home Points From India’s Historic Novartis Patent Case
The Indian Supreme Court ruling dismissing a patent application by Novartis for a new version of its leukemia drug raises five important points, writes Arvind Subramanian.



